Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

INCHEON, Korea--(BUSINESS WIRE)--Jan 14, 2026--

Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/

"2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in antibody-drug conjugates (ADCs), leveraging our innovative research and development platform to expand viable treatment options for patients with unmet needs.”

Samsung Bioepis Biosimilar Updates

Novel Therapeutics Updates

Samsung Bioepis Biosimilars Portfolio

Samsung Bioepis Biosimilar Candidates in Early Stage Development

About Samsung Epis Holdings Co., Ltd.

As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Epis NexLab Co., Ltd.

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.

1 “more than 40 countries” signifies countries where Samsung Bioepis has commercial presence, with one or more products.
2 Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.
3 Different brand names for different regions and countries.
4 “Launch” signifies launch in one or more markets and does not necessarily indicate launch in all markets worldwide

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

ST. PAUL, Minn. (AP) — The Minnesota Wild have clinched a spot in the NHL playoffs, giving them another chance to advance in the postseason for the first time since 2015.

The Wild earned a bid 75 games in after clinching last year in the 82nd and final game of the regular season. They beat league-worst Vancouver 5-2 on Thursday night to get in.

Minnesota was eliminated by the Vegas Golden Knights in the first round last year, ending coach John Hynes’ debut season.

The Wild failed to advance in seven postseason appearances between 2016 and 2023. Their deepest run in the playoffs was a trip to the conference finals in 2003 in the franchise’s third year of existence.

The Minnesota North Stars lost in the 1981 and 1991 Stanley Cup Final. They relocated to Dallas in 1993, becoming the Stars, and hoisted the Cup in 1999.

The Wild proved their commitment to contending this season by signing Kirill Kaprizov to an eight-year, $136 million contract extension — the richest deal in league history. The star winger has a team-high 83 points.

Goaltender Filip Gustavsson has won twice as many games as he’s lost while giving up a little more than 2 1/2 goals per game.

Minnesota has the league’s longest active streak of consecutive winning seasons at 14.

AP NHL: https://apnews.com/hub/NHL

Minnesota Wild left wing Matt Boldy (12) shoots the puck against the Vancouver Canucks during the third period of an NHL hockey game Thursday, April 2, 2026, in St. Paul, Minn. (AP Photo/Matt Krohn)

Minnesota Wild goaltender Filip Gustavsson defends his net against the Vancouver Canucks during the second period of an NHL hockey game Thursday, April 2, 2026, in St. Paul, Minn. (AP Photo/Matt Krohn)

Minnesota Wild right wing Ryan Hartman celebrates after his goal against the Vancouver Canucks during the third period of an NHL hockey game Thursday, April 2, 2026, in St. Paul, Minn. (AP Photo/Matt Krohn)